Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases

Paula Gish; Andrew D Mosholder; Melissa Truffa; Rosemary Johann-Liang

doi:10.1016/j.jpeds.2009.01.074

Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases

J Pediatr. 2009 Sep;155(3):432-4. doi: 10.1016/j.jpeds.2009.01.074.

Authors

Paula Gish¹, Andrew D Mosholder, Melissa Truffa, Rosemary Johann-Liang

Affiliation

¹ Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, The United States Food and Drug Administration, Silver Spring, MD 20993, USA. paula.gish@fda.hhs.gov

PMID: 19732583
DOI: 10.1016/j.jpeds.2009.01.074

Abstract

We reviewed Food and Drug Administration postmarketing reports of central nervous system (CNS) anticholinergic effects in association with oxybutynin. Taking domestic usage by age group into account, there is a disproportionately higher number of CNS adverse event cases reported in pediatric patients as compared with adult patients. CNS stimulation was prominent in the pediatric cases.

Publication types

Comparative Study

MeSH terms

Adolescent
Adult
Adverse Drug Reaction Reporting Systems / statistics & numerical data*
Age Factors
Central Nervous System / drug effects
Child
Child, Preschool
Databases as Topic
Humans
Infant
Mandelic Acids / administration & dosage
Mandelic Acids / adverse effects*
Middle Aged
Muscarinic Antagonists / administration & dosage
Muscarinic Antagonists / adverse effects*
Nervous System Diseases / chemically induced*
Nocturnal Enuresis / drug therapy
Young Adult

Substances

Mandelic Acids
Muscarinic Antagonists
oxybutynin